DSS (DSS) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting scheduled for December 4, 2024, to elect seven directors, ratify the independent auditor, and hold an advisory vote on executive compensation.
Proxy materials distributed to shareholders of record as of October 9, 2024, with voting available by mail, phone, or online.
Board recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Shareholders will vote on electing seven directors, ratifying Grassi & Co. as auditor for 2024, and approving executive compensation on an advisory basis.
No shareholder proposals were received for the 2024 meeting.
Board recommends a “FOR” vote on all proposals.
Board of directors and corporate governance
Seven director nominees listed, including Ambrose Chan Heng Fai (Chairman), José Escudero, Lim Sheng Hon Danny, William Wu Wai Leung (Lead Independent Director), Tung Moe Chan, Joanne Wong Hiu Pan, and Frankie Wong Shui Yeung.
Four directors qualify as independent under NYSE American rules.
Board committees: Audit (chaired by William Wu), Compensation and Management Resources (chaired by José Escudero), and Nominating and Corporate Governance (chaired by Frankie Wong).
All directors attended last year’s annual meeting; board and committee meetings had high attendance.
Code of Ethics adopted and available on the company website.
Latest events from DSS
- $10M shelf registration supports a multi-division growth strategy and future public offerings.DSS
Registration Filing16 Dec 2025 - Diversified issuer seeks $10M via shelf registration to fund growth across multiple business lines.DSS
Registration Filing16 Dec 2025 - Shareholders will elect directors, ratify the auditor, and vote on executive pay, with major ownership concentrated.DSS
Proxy Filing2 Dec 2025 - Proxy covers director elections, auditor ratification, compensation, and major shareholder control.DSS
Proxy Filing2 Dec 2025 - Revenue up 22% year-over-year, net loss narrows, but going concern risk persists.DSS
Q3 202514 Nov 2025 - Revenue up 27% and net loss narrowed, but going concern risk persists.DSS
Q2 202514 Aug 2025 - Q3 revenue rose 34% year-over-year, but nine-month revenue fell 28% as net losses narrowed.DSS
Q3 202413 Jun 2025 - Revenue and net loss improved sequentially as cost cuts and asset sales offset segment declines.DSS
Q2 202413 Jun 2025 - DSS, Inc. posted a $46.9M net loss in 2024, but completed the Impact BioMedical IPO.DSS
Q4 20249 Jun 2025